Thierry Brue

List of Publications by Year
in descending order

275 papers	14,604 citations	15466 65 h-index	24915 109 g-index
359 all docs	359 docs citations	359 times ranked	8282 citing authors

#	Article	IF	Citations
1	Osilodrostat in Cushing's disease: The risk of delayed adrenal insufficiency should be carefully monitored. Clinical Endocrinology, 2023, 98, 629-630.	1.2	13
2	Fully endoscopic endonasal approach for the treatment of intrasellar arachnoid cysts. Pituitary, 2022, 25, 191-200.	1.6	4
3	Lack of delayed neurocognitive side effects of Gamma Knife radiosurgery in acromegaly: the Later-Ac study. European Journal of Endocrinology, 2022, 186, 37-44.	1.9	4
4	Whole exome sequencing in a cohort of familial premature ovarian insufficiency cases reveals a broad array of pathogenic or likely pathogenic variants in 50% of families. Fertility and Sterility, 2022, 117, 843-853.	0.5	11
5	Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience. Pituitary, 2022, 25, 420-432.	1.6	7
6	Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyroidism. Endocrine, 2022, 76, 179-188.	1.1	2
7	Current and Emerging Medical Therapies in Pituitary Tumors. Journal of Clinical Medicine, 2022, 11, 955.	1.0	7
8	Clinical, radiological, and molecular diagnosis of congenital pituitary diseases causing short stature. Archives De Pediatrie, 2022, 28, 28/8S33-28/8S38.	0.4	0
9	Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?. Frontiers in Endocrinology, 2022, 13, 832361.	1.5	2
10	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. Annales D'Endocrinologie, 2022, 83, 119-141.	0.6	23
11	Impact of Cushing's syndrome on fertility and pregnancy. Annales D'Endocrinologie, 2022, 83, 188-190.	0.6	6
12	Current clinical practice for thromboprophylaxis management in patients with Cushingâ€™s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2022, 17, 178.	1.2	8
13	Prolactin immunoassay: does the high-dose hook effect still exist?. Pituitary, 2022, 25, 653-657.	1.6	10
14	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine, 2021, 71, 158-167.	1.1	8
15	Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives. Annales D'Endocrinologie, 2021, 82, 52-58.	0.6	2
16	Women's perceptions of femininity after craniopharyngioma: a qualitative study. Clinical Endocrinology, 2021, 94, 880-887.	1.2	2
17	Clinical lessons learned in constitutional hypopituitarism from two decades of experience in a large international cohort. Clinical Endocrinology, 2021, 94, 277-289.	1.2	22
18	Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary, 2021, 24, 351-358.	1.6	7

#	Article	IF	Citations
19	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.1	31
20	ESE audit on management of adult growth hormone deficiency in clinical practice. European Journal of Endocrinology, 2021, 184, 323-334.	1.9	14
21	The risks of medical treatment of prolactinoma. Annales D'Endocrinologie, 2021, 82, 15-19.	0.6	18
22	Pre-term birth in women exposed to Cushingâ€™s disease: the baby-cush study. European Journal of Endocrinology, 2021, 184, 469-476.	1.9	5
23	Corticotroph tumor progression after bilateral adrenalectomy (Nelsonâ€™s syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16.	1.9	32
24	Meningiomas in patients with long-term exposition to progestins: Characteristics and outcome. Neurochirurgie, 2021, 67, 556-563.	0.6	9
25	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312) Tj ETQq1 1 0.784314 rgBT /O	0.6	6
26	High-throughput splicing assays identify missense and silent splice-disruptive POU1F1 variants underlying pituitary hormone deficiency. American Journal of Human Genetics, 2021, 108, 1526-1539.	2.6	23
27	Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism. Journal of Clinical Lipidology, 2021, 15, 712-723.	0.6	1
28	Acromegaly in remission: a view from the partner. European Journal of Endocrinology, 2021, 185, K19-K23.	1.9	3
29	Aggressive pituitary tumours and pituitary carcinomas. Nature Reviews Endocrinology, 2021, 17, 671-684.	4.3	60
30	More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. European Journal of Endocrinology, 2021, 185, 525-538.	1.9	32
31	Novel mechanism of pituitary hormone deficiency: genetic variants shift splicing to produce a dominant negative transcription factor isoform. European Journal of Endocrinology, 2021, 185, C19-C25.	1.9	5
32	Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. European Journal of Endocrinology, 2021, 184, 1-8.	1.9	13
33	Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. Frontiers in Endocrinology, 2021, 12, 745843.	1.5	4
34	Synergistic cortisol suppression by ketoconazoleâ€“osilodrostat combination therapy. Endocrinology, Diabetes and Metabolism Case Reports, 2021, 2021, .	0.2	6
35	Surgical indications for pituitary tumors during pregnancy: a literature review. Pituitary, 2020, 23, 189-199.	1.6	18
36	Fluctuation analysis of postoperative secretory status in patients operated for acromegaly. Annales D'Endocrinologie, 2020, 81, 11-17.	0.6	1

#	Article	IF	Citations
37	Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient. Annales D'Endocrinologie, 2020, 81, 39-43.	0.6	1
38	MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushingâ€™s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study. Journal of the Endocrine Society, 2020, 4, .	0.1	3
39	MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives. Endocrine, 2020, 69, 496-503.	1.1	21
40	Hypopituitarism in Patients with Blepharophimosis and <i>FOXL2</i> Mutations. Hormone Research in Paediatrics, 2020, 93, 30-39.	0.8	8
41	Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database. Endocrine, 2020, 70, 134-142.	1.1	8
42	Parasellar Meningiomas. Neuroendocrinology, 2020, 110, 780-796.	1.2	14
43	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2964-2974.	1.8	26
44	Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients. Clinical Endocrinology, 2020, 93, 248-260.	1.2	14
45	Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocrine Connections, 2020, 9, 1178-1190.	0.8	27
46	Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. European Journal of Endocrinology, 2020, 182, 583.	1.9	36
47	Germinal defects of SDHx genes in patients with isolated pituitary adenoma. European Journal of Endocrinology, 2020, 183, 369-379.	1.9	11
48	Evaluation of an individualized education program in pituitary diseases: a pilot study. European Journal of Endocrinology, 2020, 183, 551-559.	1.9	11
49	Transcranial approach in giant pituitary adenomas: results and outcome in a modern series. Journal of Neurosurgical Sciences, 2020, 64, 25-36.	0.3	7
50	Adrenal Crisis May Occur Even In Patients With Asymptomatic Covid-19. Endocrine Practice, 2020, 26, 929-930.	1.1	4
51	SAT-291 SIX3 Is Essential for Hypothalamic and Pituitary Development. Journal of the Endocrine Society, 2020, 4, .	0.1	2
52	Ophthalmoplegic complications in transsphenoidal pituitary surgery. Journal of Neurosurgery, 2020, 133, 693-701.	0.9	2
53	Acromegaly in Carney complex. Pituitary, 2019, 22, 456-466.	1.6	20
54	Letter to the Editor: â€œWhy We Should Still Treat by Neurosurgery Patients With Cushing Disease and a Normal or Inconclusive Pituitary MRIâ€• Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5791-5792.	1.8	3

#	Article	IF	Citations
55	Genetic analysis of adult Slovenian patients with combined pituitary hormone deficiency. Endocrine, 2019, 65, 379-385.	1.1	2
56	Large Adrenal Incidentalomas Require a Dedicated Diagnostic Procedure. Endocrine Practice, 2019, 25, 669-677.	1.1	9
57	Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review. Annales D'Endocrinologie, 2019, 80, 122-127.	0.6	13
58	Clinical management of difficult to treat macroprolactinomas. Expert Review of Endocrinology and Metabolism, 2019, 14, 179-192.	1.2	6
59	Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine, 2019, 63, 563-572.	1.1	23
60	Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. Lancet Diabetes and Endocrinology,the, 2019, 7, 213-220.	5.5	86
61	Signs and symptoms of acromegaly at diagnosis: the physicianâ€™s and the patientâ€™s perspectives in the ACRO-POLIS study. Endocrine, 2019, 63, 120-129.	1.1	51
62	Heterozygous LHX3 mutations may lead to a mild phenotype of combined pituitary hormone deficiency. European Journal of Human Genetics, 2019, 27, 216-225.	1.4	17
63	SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 NaÃ¯ve Patients with Acromegaly Treated with Pegvisomant. Journal of the Endocrine Society, 2019, 3, .	0.1	3
64	X chromosome gene dosage as a determinant of congenital malformations and of age-related comorbidity risk in patients with Turner syndrome, from childhood to early adulthood. European Journal of Endocrinology, 2019, 180, 397-406.	1.9	23
65	Radiotherapy as a tool for the treatment of Cushingâ€™s disease. European Journal of Endocrinology, 2019, 180, D9-D18.	1.9	18
66	DIAGNOSIS OF ENDOCRINE DISEASE: Pituitary stalk interruption syndrome: etiology and clinical manifestations. European Journal of Endocrinology, 2019, 181, R199-R209.	1.9	50
67	MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis. European Journal of Endocrinology, 2019, 181, R107-R118.	1.9	68
68	High mortality within 90 days of diagnosis in patients with Cushingâ€™s syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	1.9	53
69	Pituitary Radiotherapy. , 2019, , 289-293.		0
70	SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience. Journal of the Endocrine Society, 2019, 3, .	0.1	0
71	Hepatic safety of ketoconazole in Cushingâ€™s syndrome: results of a Compassionate Use Programme in France. European Journal of Endocrinology, 2018, 178, 447-458.	1.9	46
72	Preoperative medical treatment in Cushingâ€™s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	1.9	37

#	Article	IF	Citations
73	Characterization of adrenocortical tumors by 18F-FDG PET/CT: Does steroid hormone hypersecretion status modify the uptake pattern?. Surgical Oncology, 2018, 27, 231-235.	0.8	4
74	MANAGEMENT OF ENDOCRINE DISEASE: Management of Cushingâ€™s syndrome during pregnancy: solved and unsolved questions. European Journal of Endocrinology, 2018, 178, R259-R266.	1.9	67
75	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 17-26.	5.5	116
76	Looking beyond the thyroid: advances in the understanding of pheochromocytoma and hyperparathyroidism phenotypes in MEN2 and of non-MEN2 familial forms. Endocrine-Related Cancer, 2018, 25, T15-T28.	1.6	22
77	Quantitative 18F-DOPA PET/CT in pheochromocytoma: the relationship between tumor secretion and its biochemical phenotype. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 278-282.	3.3	28
78	Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly. Pituitary, 2018, 21, 615-623.	1.6	20
79	Cushing Syndrome Is Associated With Subclinical LV Dysfunction and Increased Epicardial Adipose Tissue. Journal of the American College of Cardiology, 2018, 72, 2276-2277.	1.2	18
80	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology, 2018, 179, 97-108.	1.9	27
81	Genes important in the fetal development of the pituitary. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 9-12.	0.6	1
82	Long-acting FC-fusion rhGH (GX-H9) shows potential for up to twice-monthly administration in GH-deficient adults. European Journal of Endocrinology, 2018, 179, 169-179.	1.9	11
83	Lack of functional remission in Cushingâ€™s syndrome. Endocrine, 2018, 61, 518-525.	1.1	16
84	Active Cushing syndrome patients have increased ectopic fat deposition and bone marrow fat content compared to cured patients and healthy subjects: a pilot 1H-MRS study. European Journal of Endocrinology, 2018, 179, 307-317.	1.9	19
85	Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. European Journal of Endocrinology, 2018, 179, 419-427.	1.9	64
86	A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues. European Journal of Endocrinology, 2017, 176, 421-431.	1.9	21
87	MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. European Journal of Endocrinology, 2017, 176, 323-328.	1.9	27
88	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. European Journal of Endocrinology, 2017, 176, 645-655.	1.9	133
89	Lessons from monogenic causes of growth hormone deficiency. Annales D'Endocrinologie, 2017, 78, 77-79.	0.6	6
90	Gamma Knife radiosurgery for hypothalamic hamartoma preserves endocrine functions. Epilepsia, 2017, 58, 72-76.	2.6	13

#	Article	IF	Citations
91	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	1.9	42
92	Development of ACRODATÂ®, a new software medical device to assess disease activity in patients with acromegaly. Pituitary, 2017, 20, 692-701.	1.6	51
93	Gamma Knife for Cushing disease â€" time for a reappraisal?. Nature Reviews Endocrinology, 2017, 13, 628-629.	4.3	3
94	Pilot Neonatal Screening Program for Central Congenital Hypothyroidism: Evidence of Significant Detection. Hormone Research in Paediatrics, 2017, 88, 274-280.	0.8	16
95	Acromegaly at diagnosis in 3173 patients from the LiÃ¨ge Acromegaly Survey (LAS) Database. Endocrine-Related Cancer, 2017, 24, 505-518.	1.6	164
96	Increased Risk of Persistent Glucose Disorders After Control of Acromegaly. Journal of the Endocrine Society, 2017, 1, 1531-1539.	0.1	12
97	Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. Oncotarget, 2017, 8, 41044-41063.	0.8	24
98	Combined Pituitary Hormone Deficiency. , 2016, , 177-194.		1
99	MECHANISMS IN ENDOCRINOLOGY: An update in the genetic aetiologies of combined pituitary hormone deficiency. European Journal of Endocrinology, 2016, 174, R239-R247.	1.9	49
100	Prevalence ofKISS1 Receptormutations in a series of 603 patients with normosmic congenital hypogonadotrophic hypogonadism and characterization of novel mutations: a single-centre study. Human Reproduction, 2016, 31, 1363-1374.	0.4	47
101	GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency. Hormone and Metabolic Research, 2016, 48, 389-393.	0.7	18
102	Successful IVF pregnancy despite inadequate ovarian steroidogenesis due to congenital lipoid adrenal hyperplasia (CLAH): a case report. Human Reproduction, 2016, 31, 2609-2612.	0.4	21
103	The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet Journal of Rare Diseases, 2016, 11, 135.	1.2	39
104	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer, 2016, 23, 871-881.	1.6	82
105	Long-term outcome of macroprolactinomas. Annales D'Endocrinologie, 2016, 77, 641-648.	0.6	4
106	In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells. Endocrine-Related Cancer, 2016, 23, 509-519.	1.6	10
107	Bilateral adrenalectomy in the 21st century: when to use it for hypercortisolism?. Endocrine-Related Cancer, 2016, 23, R131-R142.	1.6	54
108	MANAGEMENT OF ENDOCRINE DISEASE: Outcome of adrenal sparing surgery in heritable pheochromocytoma. European Journal of Endocrinology, 2016, 174, R9-R18.	1.9	54

#	Article	IF	Citations
109	Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. Human Reproduction, 2016, 31, 782-788.	0.4	158
110	Cancerous leptomeningitis and familial congenital hypopituitarism. Endocrine, 2016, 52, 231-235.	1.1	3
111	Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly. Endocrine, 2016, 53, 210-219.	1.1	59
112	TheCables1Gene in Glucocorticoid Regulation of Pituitary Corticotrope Growth and Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 513-522.	1.8	52
113	Development of a Prediction Model of Disease Activity in Support of Clinical Practice â€“ the Acrodat Experience. Value in Health, 2015, 18, A708.	0.1	1
114	Successful pregnancies and healthy live births using frozen-thawed sperm retrieved by a new modified Hotchkiss procedure in males with retrograde ejaculation: first case series. Basic and Clinical Andrology, 2015, 25, 5.	0.8	16
115	Postoperative followâ€up of Cushing's disease using cortisol, desmopressin and coupled dexamethasoneâ€desmopressin tests: a headâ€toâ€head comparison. Clinical Endocrinology, 2015, 83, 216-222.	1.2	19
116	Dose-Dependent Dual Role of PIT-1 (POU1F1) in Somatolactotroph Cell Proliferation and Apoptosis. PLoS ONE, 2015, 10, e0120010.	1.1	2
117	Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY. Annales D'Endocrinologie, 2015, 76, 664-670.	0.6	22
118	An observational study on adrenal insufficiency in a French tertiary centre: Real life versus theory. Annales D'Endocrinologie, 2015, 76, 1-8.	0.6	14
119	THERAPY OF ENDOCRINE DISEASE: Outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. European Journal of Endocrinology, 2015, 172, R227-R239.	1.9	114
120	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer, 2015, 22, 169-177.	1.6	78
121	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocrine-Related Cancer, 2015, 22, 745-757.	1.6	155
122	Clinical Outcome, Hormonal Status, Gonadotrope Axis, and Testicular Function in 219 Adult Men Born With Classic 21-Hydroxylase Deficiency. A French National Survey. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2303-2313.	1.8	94
123	ISL1 Is Necessary for Maximal Thyrotrope Response to Hypothyroidism. Molecular Endocrinology, 2015, 29, 1510-1521.	3.7	28
124	Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. European Journal of Endocrinology, 2015, 172, 195-204.	1.9	232
125	Combined pituitary hormone deficiency: current and future status. Journal of Endocrinological Investigation, 2015, 38, 1-12.	1.8	37
126	Identifying the Deleterious Effect of Rare LHX4 Allelic Variants, a Challenging Issue. PLoS ONE, 2015, 10, e0126648.	1.1	15

#	Article	IF	Citations
127	Mutations in NFKB2and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies. BMC Medical Genetics, 2014, 15, 139.	2.1	84
128	Ghrelin Receptor (GHS-R1a) and Its Constitutive Activity in Somatotroph Adenomas: A New Co-targeting Therapy Using GHS-R1a Inverse Agonists and Somatostatin Analogs. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E2463-E2471.	1.8	5
129	Pituitary apoplexy after somatostatin analogue administration: coincidental or causative?. Clinical Endocrinology, 2014, 81, 471-473.	1.2	7
130	Bilateral neck exploration in patients with primary hyperparathyroidism and discordant imaging results: a single-centre study. European Journal of Endocrinology, 2014, 170, 719-725.	1.9	26
131	Ketoconazole in Cushing's Disease: Is It Worth a Try?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1623-1630.	1.8	231
132	Evidence for an internal and functional circadian clock in rat pituitary cells. Molecular and Cellular Endocrinology, 2014, 382, 888-898.	1.6	14
133	Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures. Endocrine-Related Cancer, 2014, 21, 691-704.	1.6	53
134	A monocentric experience of growth hormone replacement therapy in adult patients. Annales D'Endocrinologie, 2014, 75, 176-183.	0.6	7
135	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 875-884.	5.5	309
136	Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncology, The, 2014, 15, 648-655.	5.1	137
137	Management of hyperglycaemia in Cushing's disease: Expertsâ€™ proposals on the use of pasireotide. Diabetes and Metabolism, 2013, 39, 34-41.	1.4	54
138	Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clinical Endocrinology, 2013, 78, 263-270.	1.2	44
139	A new prognostic clinicopathological classification of pituitary adenomas: a multicentric caseâ€“control study of 410 patients with 8Âyears post-operative follow-up. Acta Neuropathologica, 2013, 126, 123-135.	3.9	395
140	Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. European Journal of Endocrinology, 2013, 168, 533-541.	1.9	146
141	Delayed diagnosis of Sheehan's syndrome in a developed country: a retrospective cohort study. European Journal of Endocrinology, 2013, 169, 431-438.	1.9	43
142	R31C GNRH1 Mutation and Congenital Hypogonadotropic Hypogonadism. PLoS ONE, 2013, 8, e69616.	1.1	16
143	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 651-662.	1.9	173
144	The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2012, 19, 295-299.	1.2	45

#	Article	IF	Citations
145	Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. Endocrine-Related Cancer, 2012, 19, 233-241.	1.6	72
146	Phenotypic Homogeneity and Genotypic Variability in a Large Series of Congenital Isolated ACTH-Deficiency Patients with TPIT Gene Mutations. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E486-E495.	1.8	67
147	Deficit in Anterior Pituitary Function and Variable Immune Deficiency (DAVID) in Children Presenting with Adrenocorticotropin Deficiency and Severe Infections. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E121-E128.	1.8	54
148	PROKR2 Variants in Multiple Hypopituitarism with Pituitary Stalk Interruption. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1068-E1073.	1.8	68
149	Adrenal Myelolipoma: An Unusual Cause of Bilateral Highly 18F-FDG-Avid Adrenal Masses. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2577-2578.	1.8	16
150	Inactivation of Transcription Factor Pit-1 to Target Tumoral Somatolactotroph Cells. Human Gene Therapy, 2012, 23, 104-114.	1.4	10
151	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology, 2012, 167, 887-887.	1.9	2
152	Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 981-995.	0.2	116
153	Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Annales D'Endocrinologie, 2012, 73, 225-229.	0.6	26
154	The selector gene Pax7 dictates alternate pituitary cell fates through its pioneer action on chromatin remodeling. Genes and Development, 2012, 26, 2299-2310.	2.7	124
155	Cushingâ€™s disease. Orphanet Journal of Rare Diseases, 2012, 7, 41.	1.2	46
156	Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1589-1597.	1.8	229
157	Genetic causes of combined pituitary hormone deficiencies in humans. Annales D'Endocrinologie, 2012, 73, 53-55.	0.6	17
158	Unilateral agenesis of internal carotid artery associated with congenital combined pituitary hormone deficiency and pituitary stalk interruption without HESX1, LHX4 or OTX2 mutation: a case report. Pituitary, 2012, 15, 81-86.	1.6	11
159	Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical Endocrinology, 2012, 76, 769-775.	1.2	125
160	Ipilimumab-induced hypophysitis in melanoma patients.. Journal of Clinical Oncology, 2012, 30, 8568-8568.	0.8	1
161	Truncation of PITX2 differentially affects its activity on physiological targets. Journal of Molecular Endocrinology, 2011, 46, 9-19.	1.1	12
162	Inactivation of PITX2 Transcription Factor Induced Apoptosis of Gonadotroph Tumoral Cells. Endocrinology, 2011, 152, 3884-3892.	1.4	22

#	Article	IF	Citations
163	PITX2 AND PITX1 Regulate Thyrotroph Function and Response to Hypothyroidism. Molecular Endocrinology, 2011, 25, 1950-1960.	3.7	25
164	Clinical, Biological and Genetic Analysis of 8 Cases of Congenital Isolated Adrenocorticotrophic Hormone (ACTH) Deficiency. PLoS ONE, 2011, 6, e26516.	1.1	7
165	Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. European Journal of Endocrinology, 2011, 164, 877-884.	1.9	140
166	Detection of genetic hypopituitarism in an adult population of idiopathic pituitary insufficiency patients with growth hormone deficiency. Pituitary, 2011, 14, 208-216.	1.6	13
167	Case seminar: a young female with acute hyponatremia and a sellar mass. Endocrine, 2011, 40, 325-331.	1.1	17
168	Pituitary Stem Cell Update and Potential Implications for Treating Hypopituitarism. Endocrine Reviews, 2011, 32, 453-471.	8.9	86
169	Lessons Learned from 15 Years of KIMS and 5 Years of ACROSTUDY. Hormone Research in Paediatrics, 2011, 76, 33-38.	0.8	18
170	Pituitary stalk interruption syndrome in 83 patients: novel HESX1 mutation and severe hormonal prognosis in malformative forms. European Journal of Endocrinology, 2011, 164, 457-465.	1.9	77
171	High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. European Journal of Endocrinology, 2011, 165, 509-515.	1.9	152
172	A conservative management is preferable in milder forms of pituitary tumor apoplexy. Journal of Endocrinological Investigation, 2011, 34, 502-9.	1.8	32
173	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	1.8	323
174	Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4680-4687.	1.8	111
175	Medical Treatment of Cushingâ€™s Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone. Neuroendocrinology, 2010, 92, 125-130.	1.2	53
176	Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1708-1716.	1.8	144
177	A Comparative Phenotypic Study of Kallmann Syndrome Patients Carrying Monoallelic and Biallelic Mutations in the Prokineticin 2 or Prokineticin Receptor 2 Genes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 659-669.	1.8	124
178	Cooperation between Cyclin E and p27Kip1 in Pituitary Tumorigenesis. Molecular Endocrinology, 2010, 24, 1835-1845.	3.7	76
179	Familial pituitary adenomas. Annales D'Endocrinologie, 2010, 71, 479-485.	0.6	23
180	Adenomi ipofisari. EMC - AKOS - Trattato Di Medicina, 2010, 12, 1-12.	0.0	0

#	Article	IF	Citations
181	Pharmacokinetic Evidence for Suboptimal Treatment of Adrenal Insufficiency with Currently Available Hydrocortisone Tablets. Clinical Pharmacokinetics, 2010, 49, 455-463.	1.6	53
182	Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4592-4599.	1.8	202
183	Comparative Validation of the Growth Hormone-Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency Using a Growth Hormone Assay Conforming to Recent International Recommendations. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3684-3692.	1.8	20
184	Molecular mechanisms of pituitary organogenesis: In search of novel regulatory genes. Molecular and Cellular Endocrinology, 2010, 323, 4-19.	1.6	140
185	Role of stereotactic radiosurgery in the management of pituitary adenomas. Nature Reviews Endocrinology, 2010, 6, 214-223.	4.3	99
186	Glucocorticoid receptor antagonists: a therapeutic tool in Cushing's syndrome...to be handled with care. Acta Endocrinologica, 2010, 6, 91-94.	0.1	0
187	Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up.. , 2010, , P2-85-P2-85.		0
188	Somatostatin Subtype 2 Receptor (sst2) Overexpression in Gonadotroph Mice Cell Line: Characterization and Effect on Cell Proliferation.. , 2010, , P2-303-P2-303.		0
189	Gamma Knife radiosurgery in pituitary adenomas: Why, who, and how to treat?. Discovery Medicine, 2010, 10, 107-11.	0.5	7
190	Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3400-3407.	1.8	164
191	Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY. European Journal of Endocrinology, 2009, 161, S11-S17.	1.9	17
192	A Combined Dexamethasone Desmopressin Test as an Early Marker of Postsurgical Recurrence in Cushingâ€™s Disease. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1897-1903.	1.8	44
193	Merits and pitfalls of mifepristone in Cushing's syndrome. European Journal of Endocrinology, 2009, 160, 1003-1010.	1.9	141
194	ACROSTUDY: Status Update on 469 Patients. Hormone Research in Paediatrics, 2009, 71, 34-38.	0.8	20
195	Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocrine-Related Cancer, 2009, 16, 1029-1043.	1.6	134
196	Radiotherapy and radiosurgery in acromegaly. Pituitary, 2009, 12, 3-10.	1.6	56
197	Lanreotide for the treatment of acromegaly. Advances in Therapy, 2009, 26, 600-612.	1.3	24
198	French consensus on the management of acromegaly. Annales D'Endocrinologie, 2009, 70, 92-106.	0.6	27

#	Article	IF	Citations
199	La chirurgie de premiÃ¨re intention a-t-elle encore une place dans le traitement de lâ€™acromÃ©galieÂ?. Annales D'Endocrinologie, 2009, 70, e23-e28.	0.6	0
200	Consensus franÃ§ais sur la prise en charge de lâ€™acromÃ©galie. Annales D'Endocrinologie, 2009, 70, e9-e22.	0.6	7
201	Does first-line surgery still have its place in the treatment of acromegaly?. Annales D'Endocrinologie, 2009, 70, 107-112.	0.6	15
202	Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Molecular and Cellular Endocrinology, 2008, 286, 206-213.	1.6	43
203	Congenital pituitary hormone deficiencies: role ofLHX3/LHX4genes. Expert Review of Endocrinology and Metabolism, 2008, 3, 751-760.	1.2	1
204	Somatostatin Receptor sst2 Decreases Cell Viability and Hormonal Hypersecretion and Reverses Octreotide Resistance of Human Pituitary Adenomas. Cancer Research, 2008, 68, 10163-10170.	0.4	39
205	Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. European Journal of Endocrinology, 2008, 158, 91-99.	1.9	158
206	A Novel Dysfunctional LHX4 Mutation with High Phenotypical Variability in Patients with Hypopituitarism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2790-2799.	1.8	73
207	Mutations in theAryl Hydrocarbon Receptor Interacting ProteinGene Are Not Highly Prevalent among Subjects with Sporadic Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1952-1955.	1.8	132
208	Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushingâ€™s syndrome. European Journal of Endocrinology, 2007, 157, 271-277.	1.9	84
209	Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1891-1896.	1.8	283
210	Gamma knife radiosurgery is a successful adjunctive treatment in Cushingâ€™s disease. European Journal of Endocrinology, 2007, 156, 91-98.	1.9	166
211	Chirurgie desÂprolactinomes. Annales D'Endocrinologie, 2007, 68, e35-e36.	0.6	2
212	Diagnosis andÂmanagement ofÂhyperprolactinemia: expert consensus â€“ French Society ofÂEndocrinology. Annales D'Endocrinologie, 2007, 68, 58-64.	0.6	38
213	Prolactinoma surgery. Annales D'Endocrinologie, 2007, 68, 118-119.	0.6	13
214	Diagnostic etÂprise enÂcharge desÂhyperprolactinÃ©mies â€“ Consensus d'experts deÂlaÂSociÃ©tÃ© franÃ§aise d'endocrinologie (SFE). Annales D'Endocrinologie, 2007, 68, e8-e14.	0.6	4
215	Etiological diagnosis ofÂhyperprolactinemia. Annales D'Endocrinologie, 2007, 68, 98-105.	0.6	28
216	GsÎ± overexpression and loss of GsÎ± imprinting in human somatotroph adenomas: Association with tumor size and response to pharmacologic treatment. International Journal of Cancer, 2007, 121, 1245-1252.	2.3	38

#	Article	IF	Citations
217	Gamma Knife Surgery for Epilepsy Related to Hypothalamic Hamartomas. Seminars in Pediatric Neurology, 2007, 14, 73-79.	1.0	109
218	Insuffisance ante hypophysaire post-radique. Annales D'Endocrinologie, 2006, 67, e10-e17.	0.6	0
219	Pituitary deficiency after brain radiation therapy. Annales D'Endocrinologie, 2006, 67, 303-309.	0.6	12
220	Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clinical Endocrinology, 2006, 65, 265-273.	1.2	720
221	Pituitary Transcription Factors: From Congenital Deficiencies to Gene Therapy. Journal of Neuroendocrinology, 2006, 18, 633-642.	1.2	66
222	Epilepsy related to hypothalamic hamartomas: surgical management with special reference to gamma knife surgery. Child's Nervous System, 2006, 22, 881-895.	0.6	152
223	Activin Inhibits the Human Pit-1 Gene Promoter through the p38 Kinase Pathway in a Smad-Independent Manner. Endocrinology, 2006, 147, 4351-4362.	1.4	38
224	The Role of CBP/p300 Interactions and Pit-1 Dimerization in the Pathophysiological Mechanism of Combined Pituitary Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 239-247.	1.8	25
225	Identification and Functional Analysis of the Novel S179R POU1F1 Mutation Associated with Combined Pituitary Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4981-4987.	1.8	21
226	Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes and Development, 2006, 20, 2871-2886.	2.7	213
227	Genetic Screening of Combined Pituitary Hormone Deficiency: Experience in 195 Patients. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3329-3336.	1.8	132
228	Clinical Characterization of Familial Isolated Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3316-3323.	1.8	217
229	Novel Mutations within the POU1F1 Gene Associated with Variable Combined Pituitary Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4762-4770.	1.8	111
230	An Uncommon Phenotype with Familial Central Hypogonadism Caused by a Novel PROP1 Gene Mutant Truncated in the Transactivation Domain. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4880-4887.	1.8	61
231	Congenital Isolated Adrenocorticotropin Deficiency: An Underestimated Cause of Neonatal Death, Explained byTPITGene Mutations. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1323-1331.	1.8	116
232	Outcome of Gamma Knife Radiosurgery in 82 Patients with Acromegaly: Correlation with Initial Hypersecretion. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4483-4488.	1.8	209
233	A Familial Form of Congenital Hypopituitarism Due to aPROP1Mutation in a Large Kindred: Phenotypic andin VitroFunctional Studies. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5779-5786.	1.8	75
234	The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing's disease. European Journal of Endocrinology, 2004, 151, 727-733.	1.9	43

#	Article	IF	Citations
235	A Neonatal Form of Isolated ACTH Deficiency Frequently Associated with Tpit Gene Mutations. Endocrine Research, 2004, 30, 943-944.	0.6	7
236	Gamma Knife Surgery for Epilepsy Related to Hypothalamic Hamartomas. , 2004, 91, 33-50.		65
237	Pituitary hormone deficiencies due to transcription factor gene alterations. Growth Hormone and IGF Research, 2004, 14, 442-448.	0.5	29
238	Human and mouse TPIT gene mutations cause early onset pituitary ACTH deficiency. Genes and Development, 2003, 17, 711-716.	2.7	190
239	Differential Regulation of Proopiomelanocortin and Pituitary-Restricted Transcription Factor (TPIT), a New Marker of Normal and Adenomatous Human Corticotrophs. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3050-3056.	1.8	54
240	Pseudotumor of the Pituitary due to PROP-1 Deletion. Journal of Pediatric Endocrinology and Metabolism, 2002, 15, 95-101.	0.4	23
241	Macroprolactinemia Revisited: A Study on 106 Patients. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 581-588.	1.8	195
242	Authorâ€™s Response: Macroprolactinemia Revisitedâ€”A Study on 106 Patients. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4834-4834.	1.8	1
243	A Pituitary Cell-Restricted T Box Factor, Tpit, Activates POMC Transcription in Cooperation with Pitx Homeoproteins. Cell, 2001, 104, 849-859.	13.5	491
244	PROP1 Gene Screening in Patients with Multiple Pituitary Hormone Deficiency Reveals Two Sites of Hypermutability and a High Incidence of Corticotroph Deficiency. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4529-4535.	1.8	112
245	Combined Pituitary Hormone Deficiency due to the F135C Human Pit-1 (Pituitary-Specific Factor 1) Gene Mutation: Functional and Structural Correlates. Molecular Endocrinology, 2001, 15, 411-420.	3.7	28
246	Tpit, un nouveau membre de la famille des gÃ¨nes Ã boÃ®te T, est impliquÃ© dans la dÃ©ficience isolÃ©e en ACTH. Medecine/Sciences, 2001, 17, 1203-1207.	0.0	0
247	Markers of tumor invasion are major predictive factors for the long-term outcome of corticotroph microadenomas treated by transsphenoidal adenomectomy. European Journal of Endocrinology, 2000, 143, 761-768.	1.9	13
248	Defective Retinoic Acid Regulation of the Pit-1 Gene Enhancer: A Novel Mechanism of Combined Pituitary Hormone Deficiency. Molecular Endocrinology, 1999, 13, 476-484.	3.7	66
249	An ultrarapid prognostic index in microprolactinoma surgery. Journal of Neurosurgery, 1999, 90, 1037-1041.	0.9	7
250	A Novel Mechanism of Hypopituitarism: Defective Interaction of Pit-1 with CBP. Pediatric Research, 1999, 45, 87A-87A.	1.1	0
251	The hormonal response to stress is not modified by the dramatic decrease in prolactin plasma concentration during surgery for microprolactinoma. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 502-507.	0.9	4
252	Macroprolactinemia: A Cause of Hyperprolactinemia in Childhood. Journal of Pediatric Endocrinology and Metabolism, 1997, 10, 411-7.	0.4	15

#	Article	IF	Citations
253	Prolactinomas Resistant to Bromocriptine. Obstetrical and Gynecological Survey, 1997, 52, 235-237.	0.2	0
254	Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. European Journal of Endocrinology, 1996, 135, 413-420.	1.9	104
255	Insulin-Induced Lipoatrophy in Type I Diabetes: A possible tumor necrosis factor-Â-mediated dedifferentiation of adipocytes. Diabetes Care, 1996, 19, 1283-1285.	4.3	46
256	A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency.. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2790-2796.	1.8	65
257	A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2790-2796.	1.8	67
258	Glycosylated and nonâ€glycosylated prolactin forms are increased after opioid administration as part of surgical anaesthesia. Clinical Endocrinology, 1995, 43, 213-217.	1.2	10
259	Pattern of Prolactin Diurnal Secretion in Normal Humans; Evidence for Nonlinear Dynamics. Neuroendocrinology, 1995, 62, 444-453.	1.2	10
260	3-D-FT Thin-Section MRI of Prolactin-Secreting Microadenomas. , 1994, , 354-363.		0
261	3D-FT thin sections MRI of prolactin-secreting pituitary microadenomas. Neuroradiology, 1994, 36, 376-379.	1.1	8
262	Evaluation of three-dimensional MRI exploration of prolactin-secreting microadenomas. Journal of Neuroradiology, 1993, 20, 213-25.	0.6	2
263	Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions.. Journal of Clinical Endocrinology and Metabolism, 1992, 75, 1338-1344.	1.8	30
264	Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.. Journal of Clinical Endocrinology and Metabolism, 1992, 74, 577-584.	1.8	66
265	Prolactin Isoforms Secreted by Human Prolactinomas. Hormone Research, 1992, 38, 164-170.	1.8	14
266	Prolactinomas and Resistance to Dopamine Agonists. Hormone Research, 1992, 38, 84-89.	1.8	79
267	Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine. Journal of Clinical Endocrinology and Metabolism, 1992, 74, 577-584.	1.8	55
268	Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. Journal of Clinical Endocrinology and Metabolism, 1992, 75, 540-546.	1.8	70
269	Immunoradiometric analysis of circulating human glycosylated and nonglycosylated prolactin forms: spontaneous and stimulated secretions. Journal of Clinical Endocrinology and Metabolism, 1992, 75, 1338-1344.	1.8	25
270	A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study. Fertility and Sterility, 1992, 57, 74-80.	0.5	4

#	Article	IF	Citations
271	Severe fibromyalgia after hypophysectomy for cushing's disease. Arthritis and Rheumatism, 1991, 34, 493-495.	6.7	20
272	Enlarged adenomectomy for enclosed prolactinomas: A preliminary study of 26 cases. Acta Neurochirurgica, 1990, 103, 92-98.	0.9	10
273	Macroprolactinemia Revisited: A Study on 106 Patients. , 0, .		65
274	Predictors of response to long-acting pasireotide in patients with Cushing's disease during a Phase III study. Endocrine Abstracts, 0, , .	0.0	2
275	Long-term treatment with pegvisomant (SomavertÂ®): Observations from 2090 acromegaly patients followed in ACROSTUDY. Endocrine Abstracts, 0, , .	0.0	0